55.610USD+55.610盘后交易 07/29, 20:00 (美东)
关键数据
55.600今开
56.630最高
740.19K成交量
49.91市盈率 TTM
42.74市盈率动
--股息TTM
0.93%换手率
55.610昨收
54.715最低
30.76M成交额
183.96市盈率静
3.30市净率
0.00%股息率 TTM
6.40%ROA
50.71052周最高
1.08量比
24.14M净利润
79.79M总股本
1.1150每股收益TTM
1.98Beta
6.93%ROE
22.61052周最低
3.44%振幅
72.32%毛利率
4.44B总市值
-2.74回报/风险
2.78%风险率
操作建议
Veracyte Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名23/385位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价57.83。中期看,股价处于上升通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Veracyte Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
26
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Veracyte Inc简介
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代码VCYT
公司Veracyte Inc
CEOStapley (Marc A)
网址https://www.veracyte.com/
公司股东
常见问题
Veracyte Inc(VCYT)的当前股价是多少?
Veracyte Inc(VCYT)的当前股价是 55.65。
Veracyte Inc股票的52周最高点是多少?
Veracyte Inc股票的52周最高点是50.71。
Veracyte Inc股票的52周最低点是多少?
Veracyte Inc股票的52周最低点是22.61。
现在Veracyte Inc(VCYT)的股票是买入、持有还是卖出?
根据分析师评级,Veracyte Inc(VCYT)的总体评级为买入,目标价格为57.83。
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是0.84。